Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.

In infected mammalian cells, Leishmania parasites reside within specialized compartments called parasitophorous vacuoles (LPVs). We have previously shown that Retro-2, a member of a novel class of small retrograde pathway inhibitors caused reduced LPV sizes and lower parasite numbers during experime...

Full description

Bibliographic Details
Main Authors: Evan Craig, Charles-Eugene Huyghues-Despointes, Chun Yu, Emma L Handy, Jason K Sello, Peter E Kima
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-05-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC5444862?pdf=render
_version_ 1818961035710693376
author Evan Craig
Charles-Eugene Huyghues-Despointes
Chun Yu
Emma L Handy
Jason K Sello
Peter E Kima
author_facet Evan Craig
Charles-Eugene Huyghues-Despointes
Chun Yu
Emma L Handy
Jason K Sello
Peter E Kima
author_sort Evan Craig
collection DOAJ
description In infected mammalian cells, Leishmania parasites reside within specialized compartments called parasitophorous vacuoles (LPVs). We have previously shown that Retro-2, a member of a novel class of small retrograde pathway inhibitors caused reduced LPV sizes and lower parasite numbers during experimental L. mexicana sp. infections. The purpose of this study was to determine if structural analogs of Retro-2cycl reported to have superior potency in the inhibition of retrograde pathway-dependent phenomena (i.e., polyomavirus cellular infection by polyomavrius and Shiga toxin trafficking in cells) are also more effective than the parent compound at controlling Leishmania infections. In addition to their effects on LPV development, we show that two optimized analogs of Retro-2cycl, DHQZ 36 and DHQZ 36.1 limit Leishmania amazonensis infection in macrophages at EC50 of 13.63+/-2.58μM and10.57+/-2.66μM, respectively, which is significantly lower than 40.15μM the EC50 of Retro-2cycl. In addition, these analogs caused a reversal in Leishmania induced suppression of IL-6 release by infected cells after LPS activation. Moreover, we show that in contrast to Retro-2cycl that is Leishmania static, the analogs can kill Leishmania parasites in axenic cultures, which is a desirable attribute for any drug to treat Leishmania infections. Together, these studies validate and extend the published structure-activity relationship analyses of Retro-2cycl.
first_indexed 2024-12-20T12:07:02Z
format Article
id doaj.art-bf7770f55c804ed49eee5c3ec3267f42
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-12-20T12:07:02Z
publishDate 2017-05-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-bf7770f55c804ed49eee5c3ec3267f422022-12-21T19:41:22ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352017-05-01115e000555610.1371/journal.pntd.0005556Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.Evan CraigCharles-Eugene Huyghues-DespointesChun YuEmma L HandyJason K SelloPeter E KimaIn infected mammalian cells, Leishmania parasites reside within specialized compartments called parasitophorous vacuoles (LPVs). We have previously shown that Retro-2, a member of a novel class of small retrograde pathway inhibitors caused reduced LPV sizes and lower parasite numbers during experimental L. mexicana sp. infections. The purpose of this study was to determine if structural analogs of Retro-2cycl reported to have superior potency in the inhibition of retrograde pathway-dependent phenomena (i.e., polyomavirus cellular infection by polyomavrius and Shiga toxin trafficking in cells) are also more effective than the parent compound at controlling Leishmania infections. In addition to their effects on LPV development, we show that two optimized analogs of Retro-2cycl, DHQZ 36 and DHQZ 36.1 limit Leishmania amazonensis infection in macrophages at EC50 of 13.63+/-2.58μM and10.57+/-2.66μM, respectively, which is significantly lower than 40.15μM the EC50 of Retro-2cycl. In addition, these analogs caused a reversal in Leishmania induced suppression of IL-6 release by infected cells after LPS activation. Moreover, we show that in contrast to Retro-2cycl that is Leishmania static, the analogs can kill Leishmania parasites in axenic cultures, which is a desirable attribute for any drug to treat Leishmania infections. Together, these studies validate and extend the published structure-activity relationship analyses of Retro-2cycl.http://europepmc.org/articles/PMC5444862?pdf=render
spellingShingle Evan Craig
Charles-Eugene Huyghues-Despointes
Chun Yu
Emma L Handy
Jason K Sello
Peter E Kima
Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
PLoS Neglected Tropical Diseases
title Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
title_full Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
title_fullStr Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
title_full_unstemmed Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
title_short Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
title_sort structurally optimized analogs of the retrograde trafficking inhibitor retro 2cycl limit leishmania infections
url http://europepmc.org/articles/PMC5444862?pdf=render
work_keys_str_mv AT evancraig structurallyoptimizedanalogsoftheretrogradetraffickinginhibitorretro2cycllimitleishmaniainfections
AT charleseugenehuyghuesdespointes structurallyoptimizedanalogsoftheretrogradetraffickinginhibitorretro2cycllimitleishmaniainfections
AT chunyu structurallyoptimizedanalogsoftheretrogradetraffickinginhibitorretro2cycllimitleishmaniainfections
AT emmalhandy structurallyoptimizedanalogsoftheretrogradetraffickinginhibitorretro2cycllimitleishmaniainfections
AT jasonksello structurallyoptimizedanalogsoftheretrogradetraffickinginhibitorretro2cycllimitleishmaniainfections
AT peterekima structurallyoptimizedanalogsoftheretrogradetraffickinginhibitorretro2cycllimitleishmaniainfections